There is increasing enthusiasm for exploring avenues for molecular targeted therapies of GC after the encouraging results of trastuzumab in human epidermal growth factor receptor 2 (HER2)‐positive GC patients presented by the ToGA trial.2 The gene discussed is ERBB2; the disease is gastric cancer.